ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions

Abstract Number: 1685

The Sjögren’s Tool for Assessing Response (STAR) demonstrates its ability to accurately detect treatment efficacy in 11 recent RCTs in Sjögren’s disease
Abstract Number: 1686

The Prevalence of Depressive Symptoms and Persistent Depression among Older Adults with Systemic Lupus Erythematosus (SLE)
Abstract Number: 1687

Body Esteem and Sexual Function in Women with Systemic Lupus Erythematosus
Abstract Number: 1688

Impact of Stress, Anxiety, and Depression on Fatigue as moderated by Resilience and Exposure to Trauma in Rheumatology Patients
Abstract Number: 1689

Addressing Perceived Discrimination in Lupus Care: Enhancing Patient Empowerment and Health Equity Through Education and Support
Abstract Number: 1690

Environmental Heat Exposure and Risk of Systemic Lupus Erythematosus
Abstract Number: 1691

Standardizing DXA Screening in Childhood-Onset Systemic Lupus Erythematosus at A Single Center: A Quality Improvement Initiative Using a Decision-Tree Algorithm
Abstract Number: 1692

Rheumatoid factor is associated with increased gut permeability and migration of B cells to the joint via CXCR3 in rheumatoid arthritis
Abstract Number: 1693

Characterizing ANCA-specific B Cells in ANCA-associated Vasculitis
Abstract Number: 1694

Obesity Exacerbates Autoimmunity by Dysregulating B Cell Behavior
Abstract Number: 1695

The B Cell Compartment Exhibits a Pro-Inflammatory Skewing During Progression to Rheumatoid Arthritis
Abstract Number: 1696

A multi-omics resource of B cell activation reveals genetic mechanisms for autoimmune diseases
Abstract Number: 1697

Dynamic Effects of T cell Engager Therapy on B and T cells in Autoimmune Disease.
Abstract Number: 1698

X Chromosome DNA Methylation Changes Suggest Epigenetic Contributions to Immune Dysregulation in Male Lupus
Abstract Number: 1699

Protein-coding Somatic Genetic Variation in Lymphocytes in Systemic Lupus Erythematosus

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].